Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, August 20, 2026. 12 PM-1:30 PM ET
Hear from an expert in HER2 IHC whose work has contributed to current scoring guidelines.

Webinar presenter Josef Ruschoff, MD, PhD, Former Chief Medical Officer and Co-Founder of Targos, Senior Consultant of Discovery Life Sciences, Kassel, Germany.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

To be rescheduled to a future date
Learn about digital pathology technology that is future-ready, yet practical for today’s
laboratory needs.

Webinar presenters Scott Hammond, Senior Systems Consultant, Digital Pathology Division, Wexner Medical Center, Department of Pathology, and Ursula Hofer, Imaging Technologist, Pathology Digital Imaging Lab, Wexner Medical Center, Department of Pathology, and Sandra Banky, PA(ASCP), Director of Operations, Wexner Medical Center, Department of Pathology.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

Qiagen expands portfolio for MRD testing with strategic partnerships

September 2025—Qiagen is expanding its oncology diagnostics portfolio with two strategic partnerships to advance the use of minimal residual disease testing in clinical trials to support pharma co-development projects for companion diagnostics. Tracer Biotechnologies, a developer of blood-based molecular diagnostics for cancer, is working with Qiagen to create companion diagnostics for MRD testing in solid tumors. The assays, for use on the QIAcuity digital PCR platform, are designed to enable the use of minimally invasive blood samples to monitor residual disease with high sensitivity.

Quest introduces testing for Oropouche virus

September 2025—Quest Diagnostics has launched a diagnostic laboratory test for the Oropouche virus, an emerging virus in the Americas that is spread to people by infected biting midges and some species of mosquitoes. The viral disease presents clinically with symptoms that overlap with those of other arboviral diseases such as Dengue, Zika, and chikungunya. Quest’s laboratory in San Juan Capistrano, Calif., will perform the test using PCR technology, with serology testing to follow later this quarter.

C2N launches RUO blood tests for Alzheimer’s disease

September 2025—C2N Diagnostics has launched two plasma assays for research use only. C2N eMTBR-tau243 (endogenous microtubule binding region) is a blood test that selectively detects a specific region of tau; this fragment has been shown to closely track insoluble tau aggregates within neurofibrillary tangles in Alzheimer’s disease. The assay builds on the existing C2N eMTBR-tau243 test in cerebrospinal fluid launched by the company nearly two years ago. C2N obtained exclusive rights for these technologies from the Bateman Lab at WashU Medicine, St. Louis, Mo. The company plans to integrate the new plasma C2N eMTBR-tau243 assay into clinical routine in the future.

Bio-Rad launches four ddPCR platforms

September 2025—Bio-Rad Laboratories has launched four Droplet Digital PCR platforms, which include the company’s QX Continuum ddPCR system and the QX700 series of ddPCR platforms, acquired as part of Bio-Rad’s recent purchase of Stilla Technologies. The QX Continuum ddPCR system is designed for translational research applications and features a qPCR-like workflow, four-color multiplexing, and up to eight discrete thermal profiles per plate. The QX700 series consists of three ddPCR instruments designed for academic research, environmental testing, cell and gene therapy, and biopharma quality control workflows. The systems enable seven-color multiplexing, can process more than 700 samples per day, and include easy-to-use software for streamlined data interpretation.

Copan announces leadership transition in medical and scientific affairs

September 2025—Copan Diagnostics has appointed Hema Kapoor, MD, D(ABMM), as director of medical and scientific affairs for the Americas, succeeding Susan Sharp, PhD, D(ABMM), who will retire this month following more than three decades of distinguished service to clinical microbiology. Dr. Sharp joined Copan in 2018, after a career spanning more than 30 years as a clinical microbiologist, educator, and industry leader. She previously served as chief of microbiology at Kaiser Permanente and held leadership roles at the American Society for Microbiology, including chair of the committee on laboratory practices and past president. A diplomate of the American Board of Medical Microbiology and fellow of the American Academy of Microbiology, Dr. Sharp has been recognized with ASM’s highest clinical honor, the BioMérieux Sonnenwirth Award, and the ABMM Professional Recognition Award. At Copan, her leadership has been defined by keen insight and a steadfast advocacy for advancing microbiology.

Labcorp, NowDx collaborate to expand rapid syphilis testing

September 2025—Labcorp and NowDiagnostics are collaborating to expand access to rapid syphilis testing. The companies will distribute First to Know Syphilis Test kits at no cost to select community-based public health organizations across the United States. Labcorp and NowDx distributed kits to more than 15 organizations across the country, including to LGBTQ+ health centers, HIV/AIDS care providers, and safety-net clinics. Labcorp serves as the exclusive commercial laboratory offering the test for health care providers as well as directly to consumers

Qiagen, Incyte to develop CDx for patients with myeloproliferative neoplasms

September 2025—Qiagen is collaborating with Incyte to develop a novel diagnostic panel to support Incyte’s portfolio of investigational therapies, including Incyte’s monoclonal antibody INCA033989, for patients with myeloproliferative neoplasms. Under the terms of the master collaboration agreement, Qiagen will develop a multi­modal panel using next-generation sequencing technology for detecting clinically relevant gene alterations in hematological malignancies. The panel will be validated using the Illumina NextSeq 550Dx.

Illumina launches TruSight Oncology 500 v2 research assay

September 2025—Illumina has launched TruSight Oncology 500 version 2, the next generation of the company’s flagship pancancer next-generation sequencing assay that enables in-house comprehensive genomic profiling from formalin-fixed, paraffin-embedded tissue for oncology research. A key enhancement of the new assay is fully integrated homologous recombination deficiency analysis included for every sample, powered by a gold-standard genomic instability scoring algorithm licensed from Myriad Genetics. Other updates include more sensitive variant calling and improved coverage of difficult genomic regions. The new kit has 50 percent less packaging and 70 percent fewer tubes.

ArteraAI Prostate gets breakthrough device designation

September 2025—The FDA has granted breakthrough device designation to Artera’s ArteraAI Prostate, an AI precision medicine tool intended to assist clinicians with risk-based decisions for patients with localized prostate cancer. ArteraAI Prostate analyzes digital pathology images of a patient’s prostate cancer biopsy slide to prognosticate long-term outcomes, such as 10-year risk of distant metastasis and prostate-cancer specific mortality, to help clinicians determine the most appropriate treatment option.

New England Biolabs launches NEBNext library prep kit

September 2025—New England Biolabs launched the NEBNext Low-bias Small RNA library prep kit, designed to minimize biased representation of small RNA species in sequencing data. A novel splint adaptor increases the diversity of interactions, facilitating ligation and increasing sensitivity, with a streamlined, simplified protocol. As a result, researchers can analyze all RNA species present in biologically relevant samples. Standard and 2’-O-methylated samples can also be processed using the same protocol, with multiplexing enabled through up to 480 compatible unique dual index primer pairs (available separately). Total workflow time is approximately 3.5 hours and the shelf life is 18 months.

MARKETPLACE

TRENDING